Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials
- PMID: 17449169
- DOI: 10.1016/j.eururo.2007.03.070
Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials
Abstract
Objective: To analyze the relationship between mean volume voided per micturition and number of daytime micturitions.
Methods: We reviewed data from randomized clinical trials on the medical treatment of overactive bladder published in the international literature between 1997 and 2004. Fourteen studies including data on these two parameters were identified.
Results: Six studies compared tolterodine with placebo, two tolterodine and oxybutynin with placebo, two tolterodine with oxybutynin, two solifenacin and tolterodine with placebo, one oxybutynin CR with oxybutynin IR, and one different doses of solifenacin. The correlation between the percent change in the mean voided volume and in the number of daytime micturitions was assessed using the Spearman rank correlation coefficient (r), with r=-0.67 for all the studies. For groups of patients treated with each drug, we found r=-0.09 for oxybutynin, r=-0.59 for tolterodine, r=-0.85 for solifenacin, and r=-0.34 for placebo.
Conclusion: The results of this analysis suggest that in the evaluation of the efficacy of a drug for overactive bladder, the mean volume voided per micturition may be a useful measure of efficacy.
Similar articles
-
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.BJU Int. 2010 Aug;106(4):506-14. doi: 10.1111/j.1464-410X.2009.09160.x. Epub 2010 Feb 3. BJU Int. 2010. PMID: 20132203
-
A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.Curr Med Res Opin. 2008 Aug;24(8):2173-9. doi: 10.1185/03007990802234829. Epub 2008 Jun 18. Curr Med Res Opin. 2008. PMID: 18565239 Clinical Trial.
-
Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.J Obstet Gynaecol Res. 2011 Aug;37(8):1084-91. doi: 10.1111/j.1447-0756.2010.01493.x. Epub 2011 Apr 19. J Obstet Gynaecol Res. 2011. PMID: 21501328 Clinical Trial.
-
Tolterodine for treatment of overactive bladder.Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.
-
New strategies for medical management of overactive bladder in children.Curr Opin Urol. 2010 Jul;20(4):313-7. doi: 10.1097/MOU.0b013e32833aa185. Curr Opin Urol. 2010. PMID: 21475074 Review.
Cited by
-
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.Adv Ther. 2021 Nov;38(11):5452-5464. doi: 10.1007/s12325-021-01902-8. Epub 2021 Sep 18. Adv Ther. 2021. PMID: 34537953 Free PMC article.
-
Neurogenic Lower Urinary Tract Dysfunction in Asymptomatic Patients with Multiple Sclerosis.Biomedicines. 2022 Dec 15;10(12):3260. doi: 10.3390/biomedicines10123260. Biomedicines. 2022. PMID: 36552016 Free PMC article.
-
Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis.Diagnostics (Basel). 2022 Jan 13;12(1):191. doi: 10.3390/diagnostics12010191. Diagnostics (Basel). 2022. PMID: 35054358 Free PMC article.
-
Neurogenic Lower Urinary Tract Symptoms, Fatigue, and Depression-Are There Correlations in Persons with Multiple Sclerosis?Biomedicines. 2023 Aug 4;11(8):2193. doi: 10.3390/biomedicines11082193. Biomedicines. 2023. PMID: 37626690 Free PMC article.
-
Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety.Int Urogynecol J. 2012 Oct;23(10):1337-44. doi: 10.1007/s00192-012-1696-0. Epub 2012 Mar 13. Int Urogynecol J. 2012. PMID: 22411206
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical